This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The paper was presented at the International Conference on PharmaceuticalResearch and Development (IPRDC) in Kuala Lumpur, Malaysia, in June 2017. According to Zion Market Research, the global generic market is growing at more than 10 percent per year and is expected to reach approximately $380 billion by 2021.
This could spell high-stake consequences for consumers whose privacy and safety could be at risk if AI models are not regulated. As of June 2021 , companies such as Bristol Myers Squibb , Bayer and Pfizer led the AI deals space for the pharmaceutical sectors. Major AI deals in 2022. FDA and EMA action.
Based on preclinical research for their impact on aging, well-known drugs like metformin and rapamycin are already being considered for off-label usage, due to their accepted safety profile and cost-effectiveness. We need to act decisively now and start to do the research really diligently.”
Pharmaceuticalresearch has long relied on non-human primate models for early-stage discoveries, but their use continues to cause controversy. Globally, non-human primates make up a relatively small percentage of the animals used in research. In 2021, they accounted for 0.2% of animal testing in the UK and around 0.5%
7 It is currently being evaluated in a Phase Ib/IIa clinical study, demonstrating to date a good safety profile. While favourable safety has been reported up to the Phase II, the relevance of targeting the C-terminal portion of Abeta still needs to be confirmed.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content